ZA200300336B - Clear aqueous anaesthetic composition. - Google Patents

Clear aqueous anaesthetic composition. Download PDF

Info

Publication number: ZA200300336B
Authority: ZA; South Africa
Prior art keywords: propofol; pharmaceutical composition; parenteral administration; clear aqueous; autoclaved
Prior art date: 2000-06-21

Application number

ZA200300336A

Other languages

English (en)

Inventor

Pai Srikanth Annappa

Rivankar Sangeeta Hanurmesh

Kocharekar Shilpa Sudhakar

Original Assignee

Bharat Serums & Vaccines Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-21

Filing date

2003-01-13

Publication date

2004-04-08

2003-01-13 Application filed by Bharat Serums & Vaccines Ltd filed Critical Bharat Serums & Vaccines Ltd

2004-04-08 Publication of ZA200300336B publication Critical patent/ZA200300336B/en

Links

239000000203 mixture Substances 0.000 title claims description 58
230000003444 anaesthetic effect Effects 0.000 title description 4
OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims description 120
229960004134 propofol Drugs 0.000 claims description 120
239000000243 solution Substances 0.000 claims description 74
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
238000000034 method Methods 0.000 claims description 64
229920000858 Cyclodextrin Polymers 0.000 claims description 55
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
238000007911 parenteral administration Methods 0.000 claims description 38
239000008194 pharmaceutical composition Substances 0.000 claims description 38
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
DCQLZTSRKLWEAB-UHFFFAOYSA-N ac1ndudu Chemical compound O1C(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC(C(OCC(C)O)C2OCC(C)O)C(COCC(O)C)OC2OC(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC2C(OCC(C)O)C(OCC(C)O)C1OC2COCC(C)O DCQLZTSRKLWEAB-UHFFFAOYSA-N 0.000 claims description 17
238000003756 stirring Methods 0.000 claims description 17
239000003960 organic solvent Substances 0.000 claims description 16
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 13
239000000872 buffer Substances 0.000 claims description 13
235000011187 glycerol Nutrition 0.000 claims description 13
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
229910052757 nitrogen Inorganic materials 0.000 claims description 11
239000000654 additive Substances 0.000 claims description 10
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
238000010668 complexation reaction Methods 0.000 claims description 9
239000002904 solvent Substances 0.000 claims description 9
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 8
239000003085 diluting agent Substances 0.000 claims description 8
239000003963 antioxidant agent Substances 0.000 claims description 7
235000006708 antioxidants Nutrition 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
239000006201 parenteral dosage form Substances 0.000 claims description 6
239000004471 Glycine Substances 0.000 claims description 4
239000000706 filtrate Substances 0.000 claims description 4
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 3
239000002202 Polyethylene glycol Substances 0.000 claims description 3
229960004308 acetylcysteine Drugs 0.000 claims description 3
235000010323 ascorbic acid Nutrition 0.000 claims description 3
229960005070 ascorbic acid Drugs 0.000 claims description 3
239000011668 ascorbic acid Substances 0.000 claims description 3
239000007979 citrate buffer Substances 0.000 claims description 3
230000000536 complexating effect Effects 0.000 claims description 3
229960001484 edetic acid Drugs 0.000 claims description 3
238000001914 filtration Methods 0.000 claims description 3
239000008363 phosphate buffer Substances 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
239000004296 sodium metabisulphite Substances 0.000 claims description 3
235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
-1 2- hydroxypropyl Chemical group 0.000 claims description 2
239000008364 bulk solution Substances 0.000 claims description 2
239000000084 colloidal system Substances 0.000 claims description 2
238000010926 purge Methods 0.000 claims description 2
238000007789 sealing Methods 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims 20
ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 claims 18
239000004615 ingredient Substances 0.000 description 14
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000011521 glass Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
239000007864 aqueous solution Substances 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
239000008121 dextrose Substances 0.000 description 5
238000004659 sterilization and disinfection Methods 0.000 description 5
229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
235000019796 monopotassium phosphate Nutrition 0.000 description 4
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
230000001476 alcoholic effect Effects 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
238000001949 anaesthesia Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000003193 general anesthetic agent Substances 0.000 description 2
230000036512 infertility Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
230000036407 pain Effects 0.000 description 2
239000008389 polyethoxylated castor oil Substances 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940124326 anaesthetic agent Drugs 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000002869 intravenous anesthetic agent Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000001508 potassium citrate Substances 0.000 description 1
229960002635 potassium citrate Drugs 0.000 description 1
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
235000011082 potassium citrates Nutrition 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
238000013190 sterility testing Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nanotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Crystallography & Structural Chemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Anesthesiology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200300336A 2000-06-21 2003-01-13 Clear aqueous anaesthetic composition. ZA200300336B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IN573MU2000 IN187686B (da)	2000-06-21	2000-06-21

Publications (1)

Publication Number	Publication Date
ZA200300336B true ZA200300336B (en)	2004-04-08

Family

ID=11097257

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200300336A ZA200300336B (en)	2000-06-21	2003-01-13	Clear aqueous anaesthetic composition.

Country Status (26)

Country	Link
US (1)	US7138387B2 (da)
EP (1)	EP1299095B1 (da)
JP (1)	JP4907833B2 (da)
KR (1)	KR100810066B1 (da)
CN (1)	CN1254237C (da)
AP (1)	AP2002002674A0 (da)
AT (1)	ATE267592T1 (da)
AU (2)	AU2001235972B2 (da)
BG (1)	BG107463A (da)
BR (1)	BR0017268A (da)
CA (1)	CA2414064C (da)
DE (1)	DE60011149T2 (da)
DK (1)	DK1299095T3 (da)
EA (1)	EA005589B1 (da)
ES (1)	ES2222271T3 (da)
HU (1)	HUP0301646A3 (da)
IL (1)	IL153387A0 (da)
IN (1)	IN187686B (da)
MX (1)	MXPA02012611A (da)
NO (1)	NO20025999L (da)
NZ (1)	NZ523643A (da)
PL (1)	PL359624A1 (da)
PT (1)	PT1299095E (da)
WO (1)	WO2001097796A1 (da)
YU (1)	YU2703A (da)
ZA (1)	ZA200300336B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN188917B (da) *	2000-12-07	2002-11-23	Bharat Surums & Vaccines Ltd
US7034013B2 (en)	2001-03-20	2006-04-25	Cydex, Inc.	Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20050042280A1 (en) *	2001-12-28	2005-02-24	Rogers Tracey L.	Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
CA2474710A1 (en) *	2002-02-01	2003-08-07	Shimoda Biotech (Pty) Ltd	Freeze-dried pharmaceutically acceptable inclusion complexes of propofol and cyclodextrin
KR101145692B1 (ko) *	2002-07-29	2012-05-25	트렌스폼 파마수티컬스 인코퍼레이티드	수성 2,6-디이소프로필페놀 약제학적 조성물
US7550155B2 (en)	2002-07-29	2009-06-23	Transform Pharmaceuticals Inc.	Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
US20050004002A1 (en) *	2002-12-09	2005-01-06	American Bioscience, Inc.	Compositions and methods of delivery of pharmacological agents
KR20060130646A (ko) *	2004-01-14	2006-12-19	가부시키가이샤 오츠까 세이야꾸 고죠	프로포폴 함유 지방 유제
BRPI0515181A (pt) *	2004-09-13	2008-07-22	Bharat Serums & Vaccines Ltd	composição de óleo-em-água estéril para administração intravenosa, uso de um monoglicerìdeo e processo de preparação de uma composição para administração intravenosa
CN101287447B (zh) *	2005-08-12	2012-10-24	印度血清及疫苗有限公司	包含丙泊酚的水性麻醉剂组合物
WO2007128866A2 (en) *	2006-05-09	2007-11-15	Novobion Oy	Novel chemical compositions
US8563221B2 (en) *	2008-03-11	2013-10-22	3M Innovative Properties Company	Phototools having a protective layer
WO2010148288A2 (en) *	2009-06-19	2010-12-23	Lyotropic Therapeutics, Inc.	Pharmaceutical formulations with low aqueous levels of free unbound drug
WO2011011167A2 (en)	2009-07-21	2011-01-27	3M Innovative Properties Company	Curable composition, method of coating a phototool, and coated phototool
CN102686642B (zh)	2009-09-16	2016-06-29	3M创新有限公司	氟化涂料和用其制作的底片
CN102549042B (zh)	2009-09-16	2015-01-28	3M创新有限公司	氟化涂料和用其制作的底片
US8268067B2 (en) *	2009-10-06	2012-09-18	3M Innovative Properties Company	Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) *	2010-01-14	2011-07-20	SapioTec GmbH	Flurankomplex
DK2484350T3 (da) *	2011-02-04	2016-08-01	Norbert Univ -Prof Dr Med Roewer	Farmaceutisk præparat, indeholdende et kompleks af et propofolsalt med en cyclodextrin
AU2013273764B2 (en) *	2011-11-29	2016-05-05	Zoetis Services Llc	Pharmaceutical compositions
ES2784629T3 (es) *	2011-11-29	2020-09-29	Jurox Pty Ltd	Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
CN103263404B (zh) *	2012-04-28	2017-12-01	中国人民解放军军事医学科学院放射与辐射医学研究所	一种复合麻醉药物
HUE056838T2 (hu)	2012-08-21	2022-04-28	Sage Therapeutics Inc	Allopregnanolon makacs epileptikus állapot kezelésére
EP3407875A4 (en) *	2016-01-29	2019-09-04	Cuda Anesthetics, LLC	AQUEOUS PHARMACEUTICAL FORMULATION WITH PROPOFOL
FR3117337B1 (fr)	2020-12-10	2023-04-28	Centre Hospitalier Univ De Lille	Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA962214B (en) *	1995-04-10	1996-10-07	Farmarc Nederland Bv	Pharmaceutical composition

2000
- 2000-06-21 IN IN573MU2000 patent/IN187686B/en unknown
- 2000-12-14 CA CA2414064A patent/CA2414064C/en not_active Expired - Fee Related
- 2000-12-14 AT AT00991825T patent/ATE267592T1/de active
- 2000-12-14 BR BR0017268-5A patent/BR0017268A/pt not_active Application Discontinuation
- 2000-12-14 PT PT00991825T patent/PT1299095E/pt unknown
- 2000-12-14 PL PL00359624A patent/PL359624A1/xx unknown
- 2000-12-14 AU AU2001235972A patent/AU2001235972B2/en not_active Ceased
- 2000-12-14 YU YU2703A patent/YU2703A/sh unknown
- 2000-12-14 DK DK00991825T patent/DK1299095T3/da active
- 2000-12-14 ES ES00991825T patent/ES2222271T3/es not_active Expired - Lifetime
- 2000-12-14 AU AU3597201A patent/AU3597201A/xx active Pending
- 2000-12-14 AP APAP/P/2002/002674A patent/AP2002002674A0/en unknown
- 2000-12-14 US US10/296,765 patent/US7138387B2/en not_active Expired - Lifetime
- 2000-12-14 JP JP2002503273A patent/JP4907833B2/ja not_active Expired - Fee Related
- 2000-12-14 HU HU0301646A patent/HUP0301646A3/hu unknown
- 2000-12-14 KR KR1020027017362A patent/KR100810066B1/ko not_active Expired - Fee Related
- 2000-12-14 DE DE60011149T patent/DE60011149T2/de not_active Expired - Lifetime
- 2000-12-14 MX MXPA02012611A patent/MXPA02012611A/es active IP Right Grant
- 2000-12-14 NZ NZ523643A patent/NZ523643A/en not_active IP Right Cessation
- 2000-12-14 EA EA200300047A patent/EA005589B1/ru not_active IP Right Cessation
- 2000-12-14 CN CNB008198292A patent/CN1254237C/zh not_active Expired - Fee Related
- 2000-12-14 IL IL15338700A patent/IL153387A0/xx not_active IP Right Cessation
- 2000-12-14 EP EP00991825A patent/EP1299095B1/en not_active Expired - Lifetime
- 2000-12-14 WO PCT/IN2000/000124 patent/WO2001097796A1/en active IP Right Grant
2002
- 2002-12-13 NO NO20025999A patent/NO20025999L/no not_active Application Discontinuation
2003
- 2003-01-13 ZA ZA200300336A patent/ZA200300336B/en unknown
- 2003-01-16 BG BG107463A patent/BG107463A/xx unknown

Also Published As

Publication number	Publication date
IL153387A0 (en)	2003-07-06
AU2001235972B2 (en)	2005-07-21
DE60011149D1 (de)	2004-07-01
MXPA02012611A (es)	2004-07-30
EA005589B1 (ru)	2005-04-28
CA2414064C (en)	2013-01-08
BG107463A (en)	2003-11-28
BR0017268A (pt)	2003-05-27
PL359624A1 (en)	2004-08-23
NO20025999D0 (no)	2002-12-13
NZ523643A (en)	2004-05-28
DK1299095T3 (da)	2004-10-11
ATE267592T1 (de)	2004-06-15
US20040014718A1 (en)	2004-01-22
KR100810066B1 (ko)	2008-03-05
AU3597201A (en)	2002-01-02
IN187686B (da)	2002-06-08
AP2002002674A0 (en)	2002-12-31
DE60011149T2 (de)	2005-07-07
WO2001097796A1 (en)	2001-12-27
HUP0301646A2 (hu)	2003-09-29
CN1254237C (zh)	2006-05-03
JP4907833B2 (ja)	2012-04-04
PT1299095E (pt)	2004-10-29
CA2414064A1 (en)	2001-12-27
HUP0301646A3 (en)	2005-06-28
EP1299095A1 (en)	2003-04-09
YU2703A (sh)	2006-03-03
EP1299095B1 (en)	2004-05-26
KR20030023875A (ko)	2003-03-20
JP2003535893A (ja)	2003-12-02
CN1454085A (zh)	2003-11-05
ES2222271T3 (es)	2005-02-01
EA200300047A1 (ru)	2003-06-26
NO20025999L (no)	2002-12-13
US7138387B2 (en)	2006-11-21

Publication	Publication Date	Title
ZA200300336B (en)	2004-04-08	Clear aqueous anaesthetic composition.
AU2001235972A1 (en)	2002-03-21	Clear aqueous anaesthetic composition
EP1694660B1 (en)	2009-04-08	Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
Duchêne et al.	2017	Pharmaceutical and medical applications of cyclodextrins
JP7374501B2 (ja)	2023-11-07	メロキシカム組成物、製剤及びその製造方法と応用
JP2003535893A5 (da)	2008-02-07
AU2008364165B2 (en)	2015-01-29	Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
WO2007052295A2 (en)	2007-05-10	Aqueous anaesthetic compositions comprising propofol
EP1535916A1 (en)	2005-06-01	Clathrates of butylphtualide with cyclodextrin or its derivatives,a process for their preparations and the use there of
JP7577364B2 (ja)	2024-11-05	注射用ドセタキセル組成物およびそのための調製法
JPH07316060A (ja)	1995-12-05	安定な点眼剤
KR20200059221A (ko)	2020-05-28	시포니모드를 포함하는 비경구 제형
CA2486571C (en)	2010-04-27	Pharmaceutical composition
FR2624731A1 (fr)	1989-06-23	Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique
US20100016427A1 (en)	2010-01-21	External preparation comprising prostaglandin derivative
CZ20024044A3 (cs)	2003-05-14	Čirá, vodná kompozice obsahující anestetikum
KR101066181B1 (ko)	2011-09-20	비경구 투여용 아이포스파마이드 조성물 및 이의 제조방법